Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Schering-Plough Quintiles |
---|---|
Information provided by: | Schering-Plough |
ClinicalTrials.gov Identifier: | NCT00831545 |
The study implies a 2 step study design. Patients are enrolled into 3 separate groups for melanoma, breast, and non-small cell lung cancer. In the first step, 21 patients per disease group are enrolled. If >=2 objective responses (SD, PR, or CR) out of 21 evaluable patients are observed, enrollment continues for other 45 patients as a whole, where response will be positively evaluated if >=10 patients will respond. If <2 objective responses out of 21 evaluable patients per disease group are observed, this(ese) group(s) will no longer be treated with temozolomide.
Condition | Intervention | Phase |
---|---|---|
Metastases of Central Nervous System Melanoma Breast Neoplasm Carcinoma, Non-Small-Cell Lung |
Drug: Temozolomide |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Multicenter Phase 2 Evaluation of Temozolomide for Treatment of Brain Metastases of Either Malignant Melanoma, Breast and Non-Small Cell Lung Cancer. |
Enrollment: | 162 |
Study Start Date: | December 2000 |
Study Completion Date: | October 2006 |
Primary Completion Date: | October 2006 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Subjects with melanoma: Experimental |
Drug: Temozolomide
150 mg/m2 given once a day for 7 consecutive days (Days 1 through 7) repeated every other week until disease progression or toxicity or for a maximum of one year. After amendment, schedule was modified: a second rest week was added after the second wash-out week (Days 1 through 7, 15 through 21 every 35).
|
Subjects with breast cancer: Experimental |
Drug: Temozolomide
150 mg/m2 given once a day for 7 consecutive days (Days 1 through 7) repeated every other week until disease progression or toxicity or for a maximum of one year. After amendment, schedule was modified: a second rest week was added after the second wash-out week (Days 1 through 7, 15 through 21 every 35).
|
Subjects with non-small cell lung cancer: Experimental |
Drug: Temozolomide
150 mg/m2 given once a day for 7 consecutive days (Days 1 through 7) repeated every other week until disease progression or toxicity or for a maximum of one year. After amendment, schedule was modified: a second rest week was added after the second wash-out week (Days 1 through 7, 15 through 21 every 35).
|
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Schering-Plough ( Head, Clinical Trials Registry & Results Disclosure Group ) |
Study ID Numbers: | P02064 |
Study First Received: | January 15, 2009 |
Last Updated: | January 28, 2009 |
ClinicalTrials.gov Identifier: | NCT00831545 History of Changes |
Health Authority: | Italy: Ministry of Health |
Thoracic Neoplasms Skin Diseases Breast Neoplasms Temozolomide Melanoma Carcinoma Neuroendocrine Tumors Neuroectodermal Tumors Respiratory Tract Diseases Lung Neoplasms Nevus, Pigmented |
Neoplasms, Germ Cell and Embryonal Lung Diseases Neoplasm Metastasis Neuroepithelioma Non-small Cell Lung Cancer Antineoplastic Agents, Alkylating Nevus Alkylating Agents Carcinoma, Non-Small-Cell Lung Breast Diseases Neoplasms, Glandular and Epithelial |
Thoracic Neoplasms Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Neoplasms, Nerve Tissue Melanoma Neoplastic Processes Neoplasms by Site Pathologic Processes Respiratory Tract Diseases Lung Neoplasms Therapeutic Uses Neoplasms, Germ Cell and Embryonal Neoplasm Metastasis Nevi and Melanomas Alkylating Agents |
Breast Diseases Respiratory Tract Neoplasms Neoplasms by Histologic Type Skin Diseases Breast Neoplasms Temozolomide Pharmacologic Actions Carcinoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Lung Diseases Antineoplastic Agents, Alkylating Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial |